Development of recombinant human polyclonal antibodies for the treatment of complex human diseases

Expert Opinion on Biological Therapy

Volumn 6, Issue 9, 2006, Pages 905-912

  Tolstrup, Anne B ^b   Frandsen, Torben P ^b   Bregenholt, Søren ^a  

^a Symphogen AS   (Denmark)

^b NONE

Author keywords

Antibody; Polyclonal; Recombinant; Symplex; Sympress

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; RECOMBINANT PROTEIN;

ANIMAL; BACTERIAL INFECTION; BIOSYNTHESIS; CELL LINE; GENETIC TRANSFECTION; GENETICS; HUMAN; MOLECULAR CLONING; NEOPLASM; PEPTIDE MAPPING; PHARMACEUTICS; PROTEIN CONFORMATION; REVIEW;

ANIMALS; ANTIBODIES; BACTERIAL INFECTIONS; CELL LINE; CLONING, MOLECULAR; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; NEOPLASMS; PEPTIDE MAPPING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL; TRANSFECTION;

EID: 33749044654     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.9.905     Document Type: Review

References (46)

1. CASADEVALL A, SCHARFF MD: Return to the past: the case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. (1995) 21:150-161.
2. CASADEVALL A, DADACHOVA E, PIROFSKI LA: Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. (2004) 2:695-703. • A good review of the application of antibodies in treatment of infectious disease.
3. KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-497.
4. BREKKE OH, SANDLIE I: Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. (2003) 2:52-62. (Pubitemid 37361624)
5. REICHERT JM, ROSENSWEIG CJ, FADEN LB, DEWITZ MC: Monoclonal antibody successes in the clinic. Nat. Biotechnol. (2005) 23:1073-1078. (Pubitemid 41486385)
6. FRANTZ S: Playing dirty. Nature (2005) 437:942-943. • Discusses the principle of combining different treatment modalities in cancer therapy.
7. SHARON J, LIEBMAN MA, WILLIAMS BR: Recombinant polyclonal antibodies for cancer therapy. J. Cell. Biochem. (2005) 96:305-313. • A fine review of pAbs for the treatment of cancer.
8. SPIRIDON CI, GHETIE MA, UHR J et al.: Targeting multiple her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. (2002) 8:1720-1730. (Pubitemid 34633727)
9. SPIRIDON CI, GUINN S, VITETTA ES: A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin. Cancer Res. (2004) 10:3542-3551. (Pubitemid 38685465)
10. PERERA RM, NARITA Y, FURNARI FB et al.: Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin. Cancer Res. (2005) 11:6390-6399. (Pubitemid 41262971)
11. TONRA JR, DEEVI DS, CORCORAN E et al.: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. (2006) 12:2197-2207. • Demonstrates the advantages of combining antibodies with different target specificities for the treatment of cancer.
12. MARTINEZ I, MELERO JA: Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J. Gen. Virol. (1998) 79(Pt 9):2215-2220. (Pubitemid 28423417)
13. GERNA G, REVELLO MG, DOVIS M et al.: Synergistic neutralization of rubella virus by monoclonal antibodies to viral haemagglutinin. J. Gen. Virol. (1987) 68(Pt 7):2007-2012. (Pubitemid 17120451)
14. VOLK WA, SYNDER RM, BENJAMIN DC, WAGNER RR: Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity. J. Virol. (1982) 42:220-227.
15. KINGSFORD L: Enhanced neutralization of La Crosse virus by the binding of specific pairs of monoclonal antibodies to the G1 glycoprotein. Virology (1984) 136:265-273. (Pubitemid 14053233)
16. IORIO RM, BRATT MA: Neutralization of Newcastle disease virus by monoclonal antibodies to the hemagglutinin-neuraminidase glycoprotein: requirement for antibodies to four sites for complete neutralization. J. Virol. (1984) 51:445-451. (Pubitemid 14091435)
17. PROSNIAK M, FABER M, HANLON CA et al.: Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J. Infect. Dis. (2003) 188:53-56. (Pubitemid 36829741)
18. SANNA PP, RAMIRO-IBANEZ F, DE LOGU A: Synergistic interactions of antibodies in rate of virus neutralization. Virology (2000) 270:386-396. (Pubitemid 30333686)
19. MASCOLA JR, LOUDER MK, VANCOTT TC et al.: Potent and synergistic neutralization of human immunodeficiency virus (HIV) Type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. (1997) 71:7198-7206. (Pubitemid 27391653)
20. LI A, BABA TW, SODROSKI J et al.: Synergistic neutralization of a chimeric SIV/HIV Type 1 virus with combinations of human anti-HIV Type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res. Hum. Retroviruses (1997) 13:647-656. (Pubitemid 27210453)
21. BREGENHOLT S, JENSEN A, LANTTO J, HYLDIG S, HAURUM JS: Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Curr. Pharm. Des. (2006) 12:2007-2015. (Pubitemid 43821689)
22. PARREN PW, BURTON DR: The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. (2001) 77:195-262. (Pubitemid 33703707)
23. BREGENHOLT S, HAURUM J: Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opin. Biol. Ther. (2004) 4:387-396. (Pubitemid 38352133)
24. MONTERO-JULIAN FA, KLEIN B, GAUTHEROT E, BRAILLY H: Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood (1995) 85:917-924.
25. NOWAKOWSKI A, WANG C, POWERS DB et al.: Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA (2002) 99:11346-11350. • Elegant experiments demonstrating increased in vivo neutralisation by combining several antibodies against the same bacterial toxin.
26. KONTSEK P, BORECKY L, NOVAK M, KONTSEKOVA E, MACIKOVA I: Enhancement of neutralizing efficacy by combining three monoclonal antibodies to human interferon-alpha. Immunology (1991) 73:8-11.
27. LONBERG N: Human antibodies from transgenic animals. Nat. Biotechnol. (2005) 23:1117-1125. (Pubitemid 41486393)
28. AMIN T, CARTER G: Immunogenicity issues with therapeutic proteins. Curr. Drug Disc. (2004):20-24. (Pubitemid 39642652)
29. MEIJER PJ, ANDERSEN PS, HAAHR HM et al.: Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J. Mol. Biol. (2006) 358:764-772. •• Paper describing the method for the cloning of cognate high-affinity human antibodies.
30. CARSON KL: Flexibility - the guiding principle for antibody manufacturing. Nat. Biotechnol. (2005) 23:1054-1058. (Pubitemid 41486382)
31. KUROIWA Y, KASINATHAN P, CHOI YJ et al.: Cloned transchromosomic calves producing human immunoglobulin. Nat. Biotechnol. (2002) 20:889-894. (Pubitemid 35001125)
32. CHADD HE, CHAMOW SM: Therapeutic antibody expression technology. Curr. Opin. Biotechnol. (2001) 12:188-194. (Pubitemid 32247407)
33. KIPRIYANOV SM, LE GALL F: Generation and production of engineered antibodies. Mol. Biotechnol. (2004) 26:39-60. (Pubitemid 38174858)
34. WURM FM: Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. (2004) 22:1393-1398. (Pubitemid 39482858)
35. SORRELL DA, KOLB AF: Targeted modification of mammalian genomes. Biotechnol. Adv. (2005) 23:431-469. (Pubitemid 41315917)
36. O'GORMAN S, FOX DT, WAHL GM: Recombinase-mediated gene activation and site-specific integration in mammalian cells. Science (1991) 251:1351-1355. (Pubitemid 21916917)
37. BODE J, SCHLAKE T, IBER M et al.: The transgeneticist's toolbox: novel methods for the targeted modification of eukaryotic genomes. Biol. Chem. (2000) 381:801-813. (Pubitemid 30784510)
38. HOESS RH, ZIESE M, STERNBERG N: P1 site-specific recombination: nucleotide sequence of the recombining site. Proc. Natl. Acad. Sci. USA (1982) 79:3398-3402. (Pubitemid 12011371)
39. NAGY A: Cre recombinase: the universal reagent for genome tailoring. Genesis (2000) 26:99-109. (Pubitemid 30158089)
40. THYAGARAJAN B, OLIVARES EC, HOLLIS RP, GINSBURG DS, CALOS MP: Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol. Cell. Biol. (2001) 21:3926-3934. (Pubitemid 32476454)
41. WIBERG FC, RASMUSSEN SK, FRANDSEN TP et al.: Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol. Bioeng. (2006) 94:396-405. •• Demonstrates the feasibility of manufacturing recombinant human pAbs in a 'one-pot' reaction.
42. HUNT G, NASHABEH W: Capillary electrophoresis sodium dodecyl sulfate nongel sieving analysis of a therapeutic recombinant monoclonal antibody: a biotechnology perspective. Anal. Chem. (1999) 71:2390-2397. (Pubitemid 29307602)
43. JEFFERIS R: Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. (2005) 21:11-16. (Pubitemid 40218466)
44. RUDD PM, GUILE GR, KUSTER B et al.: Oligosaccharide sequencing technology. Nature (1997) 388:205-207. (Pubitemid 27297461)
45. BECK A, BUSSAT MC, ZORN N et al.: Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2005) 819:203-218. (Pubitemid 40521956)
46. RASMUSSEN LK, FRANDSEN TP, RASMUSSEN SK, ANDERSEN PS: WO2006/007853 A2 (2006).